The efficacy of a NKG2D-CAR, generated by genetic engineering of activated and expanded NK cells (NKAE) with the NKG2D-4-1BB-CD3z-CAR construct, was analyzed in a preclinical study for MM. The gene discussed is KLRK1; the disease is Miyoshi myopathy.